Letter by Obeyesekere Regarding Article, "Combined Cardiac Magnetic Resonance Imaging and C-Reactive Protein Levels Identify a Cohort at Low Risk for Defibrillator Firings and Death"
To the Editor:
The elegant and valuable article by Wu et al 1 reports the utility of combining high-sensitivity C-reactive protein with heterogeneous myocardial tissue (gray zone) quantification to identify a very low-risk subgroup of primary prevention implantable cardioverterdefibrillator (ICD) candidates. Given that the majority of primary prevention ICD candidates will not experience appropriate ICD therapy, tools to identify this subgroup are important. A number of prior reports based on clinical variables have also recounted the ability to identify the low-risk subgroup with far more certainty than identifying the high arrhythmic risk group. 2 The identification of the high arrhythmic risk group is challenged by the competing nature of clinical variables that also predict nonarrhythmic cardiac death (and, on occasion, noncardiac death). 2 Thus the identification of the patient with truly high arrhythmic risk who is likely to benefit from ICD therapy remains challenging. 2 Combining the primary end point to assess both cardiac death (ie, nonarrhythmic death) and arrhythmic death by Wu et al does not distinguish between the patients likely to benefit from ICD therapy due to high arrhythmic risk from those unlikely to benefit due to high nonarrhythmic cardiac death risk (ie, pump failure). The secondary end point analysis provides some insight into this data.
As discussed by Wu et al 1 and the accompanying editorial, 3 because high-sensitivity C-reactive protein is associated with both nonarrhythmic causes for death and recently reported to be associated with arrhythmic death, its discriminative ability to identify the primary prevention patient with high arrhythmic risk from the high nonarrhythmic risk patient needs to be carefully considered. Additionally, regarding gray zone analysis, mechanistically, the gray zone is likely to be more contributory to arrhythmic death than nonarrhythmic cardiac death; however, does it also contribute to nonarrhythmic cardiac death?
It also needs to be acknowledged that ICD programming favoring therapy can result in patients reaching the primary end point who may have not received necessary therapy (although deemed appropriate).
Therefore, can the authors provide data on the utility of the presented variables (individually) for predicting purely arrhythmic risk (n=30 appropriate ICD therapies) and purely nonarrhythmic cardiac death (n=15)? If these individual variables can independently predict both arrhythmic death and nonarrhythmic cardiac death, then their utility is truly only limited to identifying the lowrisk subgroup in this study, as concluded.
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